Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies.
Thangaraj AbiramalathaViraraghavan Vadakkencherry RamaswamyAnand Kumar PonnalaVenkat Reddy KallemYogeshkumar V MurkundeAlan Mathew PunnooseVivekanandhan AravindhanAbdul Kareem PullattayilPrakash AmboiramPublished in: Expert opinion on investigational drugs (2022)
Interventions that have yielded significant results in preclinical research, and that have been evaluated in a limited number of clinical trials include stem cells, erythropoietin, and melatonin. Many other therapeutic modalities evaluated in preclinical studies have been identified, but more data on their neuroprotective potential in PVL must be garnered before they can be considered for clinical trials. Because most of the tested interventions had only a partial efficacy, a combination of interventions that could be synergistic should be investigated in future preclinical studies. Furthermore, since the nature and pattern of perinatal insults to preterm brain predisposing it to PVL are substantially variable, individualized approaches for the choice of appropriate neuroprotective interventions tailored to different subgroups of preterm neonates should be explored.
Keyphrases
- clinical trial
- physical activity
- stem cells
- cell therapy
- cerebral ischemia
- low birth weight
- case control
- preterm infants
- randomized controlled trial
- mesenchymal stem cells
- drug delivery
- blood brain barrier
- risk assessment
- bone marrow
- climate change
- artificial intelligence
- brain injury
- resting state
- smoking cessation
- placebo controlled